Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022
Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022
On November 13, 2024, Syros Pharmaceuticals, Inc. (the "Company") gave notice to QIAGEN Manchester Limited ("QIAGEN") of its election to terminate the Master Collaboration Agreement dated March 7, 2022 (the "Agreement") relating to the development and commercialization of an assay as a companion diagnostic test for use with tamibarotene as a result of the failure of the Company's SELECT-MDS-1 Phase3 trial evaluating tamibarotene to meet its primary endpoint of complete response rate, which was previously disclosed on the Company's Current Report on Form 8-Kfiled with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2024. The termination will be effective 90 days following such notice.
2024年11月13日，Syros Pharmaceuticals, Inc.（"公司"）已向QIAGEN Manchester Limited（"QIAGEN"）通知其選擇終止2022年3月7日簽署的《主要合作協議》（"協議"），該協議涉及與tamibarotene一起使用的伴隨診斷測試的開發和商業化，原因是公司SELECt-MDS-1三期試驗未能達到其主要終點，即完全反應率，之前已在公司於2024年11月13日向美國證券交易委員會（"SEC"）提交的8-K表格的當前報告中披露。終止將在此通知後的90天內生效。
